Glucagon Receptor Knockout Mice Display Increased Insulin Sensitivity and Impaired β-Cell Function

  1. Heidi Sørensen1,
  2. Maria Sörhede Winzell2,
  3. Christian L. Brand1,
  4. Keld Fosgerau1,
  5. Richard W. Gelling3,
  6. Erica Nishimura1 and
  7. Bo Ahren2
  1. 1Diabetes Research Unit, Novo Nordisk, Måløv, Denmark
  2. 2Department of Clinical Sciences, Section of Medicine, Lund University, Lund, Sweden
  3. 3Department of Medicine, University of Washington, Seattle, Washington
  1. Address correspondence and reprint requests to Heidi Sørensen, Diabetes Research Unit, Novo Nordisk Park, 2760 Måløv, Denmark. E-mail: hesn{at}novonordisk.com

Abstract

In previous studies, glucagon receptor knockout mice (Gcgr−/−) display reduced blood glucose and increased glucose tolerance, with hyperglucagonemia and increased levels of glucagon-like peptide (GLP)-1. However, the role of glucagon receptor signaling for the regulation of islet function and insulin sensitivity is unknown. We therefore explored β-cell function and insulin sensitivity in Gcgr−/− and wild-type mice. The steady-state glucose infusion rate during hyperinsulinemic-euglycemic clamp was elevated in Gcgr−/− mice, indicating enhanced insulin sensitivity. Furthermore, the acute insulin response (AIR) to intravenous glucose was higher in Gcgr−/− mice. The augmented AIR to glucose was blunted by the GLP-1 receptor antagonist, exendin-3. In contrast, AIR to intravenous administration of other secretagogues was either not affected (carbachol) or significantly reduced (arginine, cholecystokinin octapeptide) in Gcgr−/− mice. In islets isolated from Gcgr−/− mice, the insulin responses to glucose and several insulin secretagogues were all significantly blunted compared with wild-type mice. Furthermore, glucose oxidation was reduced in islets from Gcgr−/− mice. In conclusion, the present study shows that glucagon signaling is required for normal β-cell function and that insulin action is improved when disrupting the signal. In vivo, augmented GLP-1 levels compensate for the impaired β-cell function in Gcgr−/− mice.

Footnotes

  • B.A. has served on an advisory panel for Novantis, Novo Nordisk.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted August 29, 2006.
    • Received March 7, 2006.
« Previous | Next Article »Table of Contents